S uperantigens (SAgs) 4 are potent immunostimulatory molecules of microbial origin that function to activate large proportions of T cells by binding as intact proteins to MHC class II molecules on APCs, and TCRs on T cells, through unconventional surfaces. These interactions displace the TCR away from MHC class II such that SAg-mediated T cell activation occurs independent of the antigenic peptide loaded into the MHC class II molecule (1) (2) (3) (4) (5) (6) (7) . The ␣␤ TCR is targeted by SAgs through the V domain of the ␤-chain (termed V␤), which subsequently leads to the activation of T cells in a V␤-specific manner (8) . In humans, the number of functional TCR V␤ gene segments is limited to ϳ50, comprising 26 major classes of ␤-chains in the TCR repertoire (9, 10) . Because SAgs may bind to more than one V␤ chain, large numbers of T cells can be activated (up to 20%), and it is this hyperactivation, with the accompanying release of massive amounts of cytokines, that is believed to result in toxic shock syndrome (11) . Due to the potential activation and proliferation of autoreactive T cells, SAgs may also be involved in some autoimmune diseases (12) . Following their initial expansion, the majority of the T cells die by apoptosis and a minority survive in anergized form (13) .
Based on the crystal structures solved for TCR-SAg and SAgpeptide-MHC (SAg-p/MHC) complexes, trimolecular (TCR-SAgp/MHC) complexes have been modeled. In the first model represented by staphylococcal enterotoxin (SE) B, SEC3, and likely streptococcal pyrogenic exotoxin (Spe) A, the SAg acts as a "wedge" between the TCR and p/MHC molecules which displaces the TCR ␤-chain away from interacting with the MHC class II ␣-chain, while permitting nonconventional interactions between the TCR ␣-chain and the MHC ␤-chain (14) . Biochemical studies have confirmed that the interaction between the CDR2 loop of the TCR ␣-chain and the MHC class II ␤-chain stabilizes the trimolecular structure (15) , resulting in an energetically cooperative TCR-SAg-p/MHC supramolecular complex that exhibits an affinity similar to that of most agonist p/MHC interactions with TCR (16) . In a second model, represented by SpeC, the SAg acts as a "bridge", which abrogates any direct contacts between the TCR and p/MHC molecules (1) . In this complex, the higher affinity interaction between SpeC and p/MHC (5) is believed to stabilize the trimolecular complex.
Recent bacterial genome sequencing projects have revealed a large number of genetically distinct SAgs present in pathogenic Staphylococcus aureus and Streptococcus pyogenes. These SAgs belong to the pyrogenic toxin class of SAgs (11) and currently there are Ͼ30 identified serotypes (17) . Even though most of these toxins share relatively low amino acid sequence identity, all characterized SAgs from this class have a conserved two-domain structure including a smaller N-terminal domain and a larger C-terminal domain with a central ␣ helix connecting the two domains (18) . Despite their similar structures, SAgs display diversity in binding to their TCR ligands as revealed by a limited number of SAg-TCR crystal structures. Atomic structures of SEB (6) , SEC3 (14) , and SpeA (1) have been characterized with a single TCR ␤-chain, mouse V␤8.2, and the SpeC structure has been solved in complex with the human TCR ␤-chain V␤2.1 (1) . In each case, the SAg binds to TCR molecules with residues positioned in the cleft between the two SAg domains, yet the structure of V␤2.1 in complex with SpeC revealed considerable binding differences compared with other SAg-␤-chain complexes. SpeC makes multiple contacts with both side chain and main chain atoms of V␤2.1, and was unique among characterized SAg-TCR interactions in that all three CDR loops were engaged, as well as the hypervariable (HV) region 4 and framework region (FR) 3 (1). In particular, the CDR3 contacts were unexpected because this loop is highly variable even within a single V␤ family due to somatic recombination. Also, the buried surface of the SpeC-V␤2.1 is comparable to that of TCR-p/MHC complexes, considerably larger than the contact surfaces for other SAg-TCR complexes (1, 6, 14) . However, the molecular basis by which particular SAgs bind to certain TCR V␤ domains but not to others, as well as why some SAgs are highly restrictive in their V␤-binding partners while others are promiscuous binders, is presently unclear.
The SpeC-V␤2.1 crystal structure (1) identified all of the intermolecular contacts that form the interface of this complex (the "structural epitope"). Structural studies alone, however, cannot provide a comprehensive understanding of the molecular basis for complex formation, because protein-protein interactions are not homogenous energetic landscapes. Instead, hot spot residues, which confer the majority of the binding energy to a given complex (the "functional epitope"), are interspersed with energetically silent residues (19 -21) . Algorithms developed to predict the energetic contribution of individual residues (22) (23) (24) (25) (26) , while greatly advanced in the past few years, do not provide accurate enough predictions to alleviate the current need to determine these values experimentally. Furthermore, protein complexes function in the context of larger biological systems, and thus, the structural and energetic dissection of a protein-protein interaction can provide a truly comprehensive understanding of the complex only when integrated with functional analysis.
To provide such a comprehensive understanding of V␤2.1 engagement by SpeC, we have mutated every SpeC residue involved in the SpeC-V␤2.1 molecular interface to alanine. We determined the binding affinities of these mutants and wild type SpeC to soluble V␤2.1 by surface plasmon resonance (SPR) analysis, as well as their functional readouts upon stimulation of both bulk T cells and an engineered V␤2.1 ϩ T cell line. Collectively, our energetic and functional data define the functional epitope on the SpeC molecular surface and provide the molecular basis for SpeC-TCR V␤ domain selectivity, cross-reactivity, and allelic discrimination.
Materials and Methods

Cloning procedures
Standard DNA manipulations were performed as described (27) using enzymes supplied from New England Biolabs in accordance with the manufacturer's instructions. Oligonucleotides were obtained from Invitrogen Life Technologies. PCRs were performed in a Peltier Thermocycler (MJ Research) with Vent DNA polymerase (Invitrogen Life Technologies) and PCR products were purified using the QIAquick PCR purification kit (Qiagen). All cloned PCR products were sequenced in their entirety at the John P. Robarts Research Institute Sequencing Facility (London, Ontario, Canada) to ensure correct mutations and PCR fidelity. Escherichia coli was cultured aerobically in Luria Bertani broth (Difco Laboratories) at 37°C, and solid medium was obtained by the addition of 1.5% (w/v) Bacto-agar (Difco). Kanamycin (50 g/ml) and ampicillin (100 g/ml) were used as selective agents as required. All reagents were made with water purified through a Milli-Q water purification system (Millipore).
SpeC mutants
For expression of the various SpeC proteins, we first generated a modified version of the E. coli expression vector pET41a (Novagen). Overlapping complementary primers were designed (5Ј-CGGTGGTGGCTCCGGT GAAAACTTGTATTTCCAAGGCAGTCC-3Ј and 5Ј-CATGGGACTGC CTTGGAAATACAAGTTTTCACCGGAGCCACCACCGGTAC-3Ј) that when annealed leave overhangs compatible with the KpnI and NcoI sites of pET41a. When ligated into these sites (to create pET41a::TEV), the pET41a enterokinase cleavage site (DDDDK) is replace with the tobacco etch virus (TEV) protease cleavage site (ENLYFQG) (28) leaving other features of the plasmid intact. Wild-type speC was PCR amplified from pET28a::speC (29) with primers SpeC-forward (5Ј-CCCATGGCAG ACTCTAAGAAAGACATTTCGAATG-3Ј; NcoI site underlined) and SpeC-reverse (5Ј-CCCGGATCCTTATTTTTCAAGATAAATATCGAA ATG-3Ј; BamHI site underlined) where the forward primer amplified speC lacking the coding region for the 27-aa signal peptide (30) . The resulting PCR product was cloned into pET41a::TEV creating an N-terminal translational fusion of GST and His 6 purification tags with SpeC, as well as the TEV site for removal of the purification tags. The various SpeC mutant proteins were generated using an overlapping megaprimer PCR method using oligonucleotides that incorporated the desired single-site mutation. SpeC proteins were expressed from E. coli BL21(DE3) (Novagen), purified by Ni 2ϩ -column chromatography, and the purification tags were removed with autoinactivation-resistant His 7 ::TEV as described (28) .
LG-2 aggregation assay
The B lymphoid cell line LG-2 was used in cell aggregation experiments (31) and was performed with all the SpeC mutant proteins as an indication of overall protein conformation and to assess the ability of the mutants to engage MHC class II. LG-2 cells (100,000 cell/ml) suspended in RPMI 1640 (Invitrogen Life Technologies) supplemented with 10% FCS (Sigma-Aldrich), 100 g/ml streptomycin (HyClone), 100 U/ml penicillin (HyClone), 2 mM L-glutamine (HyClone), 1 mM MEM sodium pyruvate (HyClone), 100 M nonessential amino acid (HyClone), and 25 mM HEPES (pH 7.2) (BioShop) were plated into each well of a 96-well plate. Afterward, 1 g of each protein was added and aggregation was monitored under an inverted microscope at various time points.
PBL proliferation measurements
The studies were reviewed and approved by University of Western Ontario Research Ethics Board for Health Sciences Research Involving Human Subjects. The ability of purified recombinant wild-type and mutant SpeC proteins to proliferate human T cells was assessed using gradient-purified human PBMCs stimulated ex vivo in 96-well microtiter plates (2 ϫ 10 5 cells/well) with serial 1/5 dilutions (in triplicate). RPMI 1640 medium supplemented as above for the LG-2 assays was used as the culture medium and cells were incubated in 5% CO 2 
Flow cytometry of activated V␤2
ϩ T cells Surface plasmon resonance V␤2.1D␤2.1J␤2.3C␤2 (herein referred to as V␤2.1) was expressed, refolded, and purified as previously described (1) . Binding affinities of V␤2.1 to immobilized SpeC and the various mutants were monitored with a BIAcore 3000 instrument (Biacore). SAgs were coupled via amine groups to a dextran matrix on CM5 sensor chips, at a total mass corresponding to ϳ500 resonance units. SEB, in an equivalent surface density, was used as a negative control surface, as no specific binding of the V␤2.1 chain to this SAg occurs. V␤2.1 was dialyzed against 10 mM Na-HEPES (pH 7.5), 150 mM NaCl, 3.4 mM EDTA, 0.005% P20 surfactant (HBS-P20) and was characterized immediately before injection by size exclusion chromatography to ensure that no aggregation was present. Measurements were conducted at 25°C by injecting increasing concentrations of V␤2.1 up to a maximum of 100 M at a flow rate of 10 l/min. Affinities (K D ) were determined by nonlinear regression analysis of equilibrium binding from multiple concentrations of injected V␤2.1 using BIAevaluation 4.1 software (Biacore).
Construction of V␤2.1 expressing Jurkat T cells and activation measurements
To allow for a functional readout for the SpeC mutants specific for the V␤2.1 chain used in the SpeC-V␤2.1 complex (1), the Jurkat T cell line JRT3-T3.5 (American Type Culture Collection) was used. This cell line lacks the endogenous V␤8.1 chain present in wild-type Jurkat T cells (32) . The leader and transmembrane DNA sequences of human V␤8.1 (33) were attached to the 5Ј and 3Ј ends of V␤2.1 cDNA, respectively, to promote surface expression and successful pairing of V␤2.1 with the endogenous V␣1. In addition, alanines at positions 13 and 191 generated for the cocrystal structure with SpeC (1) were back-mutated to the native cysteine residues. All of these modifications to the V␤2.1 cDNA were performed by sequential megaprimer PCR and the complete V␤2.1 cDNA was cloned into the unique KpnI and BamHI sites in pBIG2i (34) . This vector has an ampicillin-resistant marker for cloning purposes in E. coli, a hygromycin B-resistant marker for establishing stable cell lines and a tetracycline responsive system for the induction of the desired gene. Ten micrograms of linearized pBIG2i::V␤2.1 was electroporated into 5,000,000 JRT3-T3.5 cells using 300 V and 950 F and stable transfectants were selected using increasing concentrations of hygromycin B. JRT3-T3.5 transfected with pBIG2i alone was used as a negative control. Surface expression of V␤2.1 paired with endogenous V␣1 was induced with doxycycline at a concentration of 1 g/ml and surface expression was confirmed using FACS analysis with PE-conjugated anti-TCR Ab (eBioscience). Further verification of the expressed TCR was performed with FITC-conjugated anti-V␤2 Ab. Transfected JRT3-T3.5 were incubated with LG-2 cells (in 5:1 ratio) to provide MHC class II (HLA-DR1) in the presence of SpeC proteins (1 ng/ml) for 16 -18 h. Activation was monitored using ELISA for IL-2.
Results
SpeC mutants
The crystal structure of the SpeC-V␤2.1 complex revealed that 12 residues of SpeC collectively make up the structural epitope for binding to V␤2.1. To define the SpeC functional epitope, we performed alanine-scanning mutagenesis analysis for all SpeC residues in contact with V␤2.1. Alanine was chosen as the mutating residue to replace the side chains of the interacting residues because of its inherent attribute to minimize steric or electrostatic constrains on the tertiary structure of the protein (35) . All SpeC proteins were expressed from E. coli BL21(DE3) and purified to apparent homogeneity as determined by SDS-PAGE (data not shown). As SpeC is known to aggregate the B lymphoblastoid
LG-2 cell line through the cross-linking of MHC class II molecules expressed on these cells (31), we used this assay to confirm the point mutations did not cause gross structural defects in the mutant proteins. Each of the mutant proteins was able to aggregate LG-2 cells as expected, while a negative control SAg (SpeA) did not cause aggregation (data not shown). In addition, circular dichroism analysis confirmed that the point mutations did not induce any gross structural deviations in the proteins (data not shown).
Proliferation of human T cells by SpeC mutants
We examined the ability of each mutant to proliferate human PBMCs using standard [ 3 H]thymidine assays. The stimulatory capacity (P 50 ) is defined as the concentration of SpeC mutant protein required to reach 50% of the maximum proliferation relative to wild-type SpeC. SpeC mutants produced dose-dependent proliferation curves, whereas wild-type reached P 50 at ϳ0.273 ng/ml (Table I) . Wild-type SpeC typically reached a maximum plateau by ϳ4 ng/ml and then decreased as the concentration increased to the highest concentration tested (500 ng/ml). Of the 12 mutants, two mutants (Y15A and R181A) showed a dramatic decrease in activity and did not reach the P 50 value even at concentrations of 500 ng/ml. Based on P 50 values, most of the other SpeC mutants showed minor reductions in activity relative to wild type, with the greatest loss of activity occurring with L78A, F75A, and Y49A mutants (ϳ11-, 6-, and 5-fold reductions, respectively) ( Table I) .
Activation of V␤2 ϩ T cells by SpeC mutants
Because the majority of SpeC-targeted T cells are represented by V␤2 ϩ T cells (31) and the alanine-scanning mutants were based on the cocrystal structure with V␤2.1 (1), we evaluated the effect of the SpeC mutants on V␤2 ϩ T cells. We monitored activation of CD3 ϩ V␤2 ϩ T cells from human PBMCs using the up-regulation of CD25 as a measure of V␤2-specific T cell activation. CD25 is the ␣-chain of the high-affinity IL-2R which is up-regulated upon T cell activation and is a member of the early response gene family of naive T cells. CD25 expression gradually increases to maximum levels by day 3 after stimulation and afterward the expression level is maintained on T cells (36) . Approximately 7% of total T cells from a healthy donor are V␤2 ϩ and roughly 1% of these V␤2 ϩ T cells were routinely found CD25 ϩ in the absence of stimulation (Fig. 1) . Upon stimulation with wild-type SpeC, however, the percentage of activated V␤2 ϩ T cells, as monitored by the up-regulation of CD25, increased to ϳ7% of total T cell population with virtually no resting cells, indicating that essentially all V␤2
ϩ T cells present in the population were activated. There was also a marked increase in the percentage of activated T cells that were not V␤2 ϩ (Fig. 1A) , and these populations likely represent other SpeC-targeted V␤s. The majority of V␤2 Ϫ cells, marked by the absence of CD25, though, were not activated by SpeC, as expected.
The activation profiles for the Y15A and R181A mutants were similar to untreated cells indicating that these mutants were drastically impaired (Fig. 1B) . The activation profile for F75A and L78A mutants, consistent with their P 50 values for the complete T cell repertoire (Table I) , were also reduced (Fig. 1B) . In contrast, most of the other SpeC mutants did not markedly differ from wild type. Also of note, both the F75A and L78A mutants failed to stimulate a significant subpopulation (1.5-2%) of V␤2 ϩ T cells that were activated by wild-type SpeC (Fig. 1) . Thus, specific mutations in SpeC appear to allow for the discrimination of different alleles within a specific V␤ family.
Direct binding of V␤2.1 to SpeC mutants
To examine the interaction between the various SpeC mutants and the V␤2.1 allele used in the cocrystal structure (1), we determined the binding affinity of each mutant to V␤2.1 by SPR (Table I) . Representative profiles of equilibrium binding between immobilized wild-type and mutant SpeC proteins and V␤2.1 and their corresponding nonlinear regression analyses of binding are shown in Fig. 2 . The K D values and differences in the changes in binding free energy relative to wild type (⌬⌬G b ) of all of the interactions are listed in Table I . None of the mutants bound V␤2.1 with significantly higher affinity than did wild-type SpeC (K D ϭ 13 M).
This binding analysis between the SpeC mutants and V␤2.1 provides the energetic contribution of individual residues in stabilizing the SpeC-V␤2.1 complex. Energetically, the SpeC mutants can be divided into three groups: 1) neutral mutants (T20A, R45A, Y49A, and T180A) that had no significant change on the overall binding; 2) intermediate mutants (T18A and N79A) that decreased the binding affinity of SpeC for V␤2.1 by approximately half; and 3) critical mutants (Y15A, I19A, F75A, L78A, E178A, and R181A) that abrogated any detectable binding up to 100 M V␤2.1 (ϳ10-fold lower concentration than the wild-type SpeC-V␤2.1 K D ). This data indicates that although the binding site for V␤2.1 on the SpeC molecular surface is quite large, only a specific subset of SpeC residues is important for complex formation.
Derivation of a V␤2.1-specific functional readout
To better identify the functional epitope on SpeC, to mimic physiological conditions as closely as possible, and to determine whether the energetic contributions of the residues can be correlated to their functional contributions, we engineered the non-TCR-expressing Jurkat T cell line JRT3-T3.5 to exclusively express the V␤2.1 chain. The normal ␣␤ TCR on Jurkat T cells is comprised of the V␤8.1 chain conjugated to the V␣1 chain. However, in JRT3-T3.5, the V␤8.1 gene is defective, rendering it unable to express the paired ␣␤ TCR on the surface. Our engineered JRT3-T3.5 (eJRT3-2.1) cell line expresses the V␤2.1 chain paired with the endogenous V␣1 (data not shown). Even in the absence of the inducer doxycycline and under our conditions, we achieved almost 100% expression of the TCR (Fig. 3A) , and thus, we conducted all experiments without induction.
The eJRT3-2.1 cells were incubated with LG-2 cells (which provide a source of MHC class II molecules) in the presence of either wild-type SpeC or the individual alanine mutants. Activation was assessed by measuring IL-2 secretion by ELISA (Fig. 3B) and IL-2 expression profiles correlated to the measured affinities of the SpeC proteins. Wild-type SpeC proteins induced the highest IL-2 secretion levels by the eJRT3-2.1 cells, whereas the neutral and intermediate mutants induced similar levels of IL-2 secretion, even though the intermediate mutants exhibit affinities for V␤2.1 that are ϳ2-fold weaker. Four of the mutants (Y15A, F75A, L78A, and R181A) with no detectable binding to soluble V␤2.1 did not produce significant levels of IL-2 from eJRT3-2.1 cells. However, for the I19A and E178A mutants, which also lacked detectable binding to soluble V␤2.1 (up to 100 M), only reduced quantities of IL-2 were secreted.
Discussion
Bacterial SAgs represent a unique class of microbial toxin that has evolved to target two key immune cell receptors, the TCR and MHC class II. The collective family of bacterial SAgs includes over 30 recognized serotypes (17) , which now greatly exceeds those that have been structurally characterized with their TCR and MHC ligands. Although there exists a high degree of structural homology between these SAgs, dramatically distinct molecular architectures of the ternary TCR-SAg-p/MHC T cell signaling complexes can be formed. The most significant factor in supramolecular architecture diversity is the numerous ways in which SAgs interact with their MHC ligands. The ways in which SAgs recognize their TCR ligands, although not as radically diverse as SAg-p/MHC interactions, are also varied. This is the determining factor for which distinct subsets of T cells are activated by individual SAgs.
The crystal structure of SpeC in complex with V␤2.1 revealed that SpeC contacts included all three V␤ CDR loops, as well as FR2 and FR3/HV4 regions, and consequently the buried interface was much larger than other characterized SAg-TCR complexes, being more similar in size to typical TCR-p/MHC complexes (1). The binding characteristics of SpeC to V␤2.1 also led to the suggestion that SAgs may target their TCRs in at least three distinct ways (37) . One group, represented by SEB and SEC3, which would be highly promiscuous for T cell activation, target V␤s mainly on a conformational basis, making only contacts with V␤ main chain atoms. A second group, represented by SpeA, targets both V␤ main chain and side contacts, and would be more selective. The third group, represented by SpeC, targets only V␤ amino acid side chains, and would therefore be highly selective. Despite these multiple modes for activation of T cells, each is capable of generating a highly V␤-skewed population of T cells. This rudimentary classification of SAg-TCR recognition is severely limited by the paucity of SAg-TCR crystal structures, which are currently restricted to SEB, SEC3, and SpeA bound to mouse V␤8.2 (1, 6, 14) and SpeC bound to human V␤2.1 (1). Thus, our understanding of how each distinct SAg recognizes its particular subset of TCR V␤ domain ligands, and the molecular basis of SAg-TCR specificity and cross-reactivity, remain unclear.
Although the cocrystal structure of SpeC in complex with human V␤2.1 has provided a molecular snapshot of all contacts within this interface (1) (Fig. 4A) , it does not provide the functional and energetic requirements for this interaction. To determine the molecular basis of SpeC recognition of V␤2.1, we performed alanine-scanning mutagenesis involving all SpeC residues that contact V␤2.1. Subsequently, the wild-type and mutant SpeC proteins were subjected to a comprehensive battery of functional and energetic analyses. In this integrative approach, stimulatory capacities of bulk primary T cell populations, activation of specific V␤ subsets, binding parameters to soluble V␤2.1, as well as quantitative measures of the activation of engineered V␤2.1 ϩ Jurkat T cells were derived for each protein (Table I) .
Using primary human T cells, we have shown that SpeC residues Tyr 15 and Arg 181 are of critical importance for the recognition of virtually all human T cells (Table I and Fig. 1B) . Residues Phe 75 and Leu 78 , when mutated to alanine, resulted in the stimulation of only a subpopulation of primary V␤2 ϩ T cells. The remaining SpeC mutants showed insignificant effects on proliferation indexes for the complete T cell repertoire.
To determine the energetic contributions of each of the SpeC residues that comprise the molecular interface with V␤2.1, we performed SPR analysis. The wild-type and each of the SpeC mutants were individually immobilized and serial dilutions of soluble V␤2.1, with a maximum concentration of 100 M, were injected over each surface. As for other wild-type SAg-TCR interactions, the SpeC-V␤2.1 complex has an affinity in the midmicromolar range (K D ϭ 13 M; Table I , Fig. 2A ). Two SpeC mutants (T18A and N79A) exhibited ϳ2-fold reduced binding to V␤2.1 compared with the wild type (Fig. 2B) . Several of the SpeC mutants (T20A, R45A, Y49A, and T180A) exhibited no significant change in binding affinity relative to the wild type (Fig. 2C) . The remaining SpeC alanine mutants (Y15A, I19A, F75A , L78A, E178A, and R181A) had no detectable binding to V␤2.1, at least at concentrations as high as 100 M (Fig. 2D) .
To ascertain the V␤2.1-specific functional contributions of each SpeC residue, we engineered Jurkat T cells to exclusively express V␤2.1 receptors (eJRT3-2.1) and activated these cells with wildtype SpeC and each of the mutants. Alanine mutations at four of the critical residues (Tyr 15 , Phe 75 , Leu 78 , and Arg 181 ) did not produce significant quantities of IL-2 from eJRT3-2.1, while mutants at positions Ile 19 , Tyr 49 , and Glu 178 produced reduced amounts (Fig. 3B) . The ability of both I19A and E178A to activate eJRT3-2.1 (Fig. 3B) , despite our inability to detect binding of these mutants to V␤2.1 (Table I) , may simply be due to a sensitivity limitation of the Biacore experiments. Stabilizing forces present in the cell-based assays such as TCR ␣-chain/MHC class II ␤-chain interactions (15, 16) , that are lacking in the affinity measurements which use purified TCR ␤-chain, could account for these discrepancies. As well, the mutants with low affinities for the TCR ␤-chain may still induce transient TCR oligomerization, and thus lead to partial signaling. The two mutants with relatively minor (i.e., ϳ2-fold) reductions in binding to V␤2.1 (Thr 18 and Asn 79 ) and the remaining mutants with no apparent change in binding affinity to V␤2.1 (Thr 20 , Arg 45 , Tyr 49 , and Thr 180 ) also displayed slight reductions in IL-2 production from the engineered Jurkat T cells (Fig. 3B) . Based on the collective data, including the proliferation indexes, activation of primary V␤2 ϩ T cells, affinity measurements for soluble V␤2.1, and activation of V␤2.1-specific Jurkat T cells, we conclude that the remaining residues Thr 20 , Arg 45 , Tyr 49 , and Thr 180 play little to no role for the activation of V␤2 ϩ T cells. However, residues that were critical for the specific recognition of the human V␤2.1 allele used here also included Phe 75 and Leu 78 , while Ile 19 and Glu 178 had significant, but not critical, effects (Table I and Fig. 3B) .
The binding affinities of the various SpeC mutants to soluble V␤2.1 were correlated with the activation experiments using the eJRT3-2.1 cells. The energetic and functional contributions of individual SpeC residues to the interaction with V␤2.1 have been mapped to the surface of SpeC (Fig. 4B) The term "hot spot" is used to describe amino acid residues within a protein-protein interface that contribute significantly to the binding energy (20) . Hot spot residues typically have a nonrandom distribution within a molecular interface, but are often clustered into "hot regions" (38, 39) . The six residues identified here as important for V␤2.1 recognition fit the criteria of a single, well-defined hot region located within the center of the interface. In this way, the SpeC functional epitope is similar to many proteinprotein interactions, where most of the energetically important residues were also clustered in the center of the interface. These critical residues in the centralized hot region on the SpeC molecular surface form a high-energy binding pocket that accommodates the tip of the CDR2 loop and makes several specific hydrogen bonds and van der Waals interactions with the side chain of the inserted residue Ser 52a (Fig. 4C) . Because essentially all of the binding energy is centered on the engagement of the CDR2 loop in this hot region, and the SpeC surface that binds the loop is highly concave (at least in relation to most protein-protein interfaces), it is possible that small molecules could be developed that inhibit the SpeC-V␤2.1 interaction, and thus, could serve as potential therapeutics of SpeC-mediated disease.
The TCR CDR3 loops are the most variable regions of the TCR, generated through random rearrangement of the various TCR gene segments (40) . These loops also make the most contacts with the antigenic peptide and are responsible for different peptide specificities between different V␤s. Of bacterial SAgs, only the Mycoplasma arthritidis mitogen has been shown to be functionally dependent on distinct residues of the CDR3 loop for T cell activation (41) ϩ T cells, an unexpected result if indeed CDR3 contacts were functionally relevant. Although the N79A mutant had wild-type activity for activation of V␤2 ϩ T cells (Fig. 1B) , it did exhibit minor reductions in binding affinity to soluble V␤2.1 (Table I) and IL-2 production by eJRT3-2.1 cells (Fig. 3B) . This residue most likely influences CDR1, and not CDR3, loop interactions and based on the collective data, we conclude that CDR3 plays no significant role in SpeC engagement of V␤2.1.
SpeC has been reported to target T cells expressing human V␤s 2, 3, 4, 12, and 15, with the majority being V␤2 ϩ T cells (31) . Only two V␤ families contain the CDR2 Ser 52a insertion, V␤2 and V␤4 (9) , and SpeC has also been reported to activate both of these V␤s. However, V␤2
ϩ T cells are activated ϳ15-fold higher compared with V␤4 ϩ T cells (31) . Differences between the reactivity for these two V␤s have been proposed to be due to a second unique residue insertion (Phe 27a ), found only in the CDR1 loop of V␤2 alleles. Although Phe 27a is not contacted by SpeC, this insertion induces an altered conformation of the CDR1 loop such that it positions the loop to make contacts with SpeC (1). The remaining SpeC-targeted V␤ domains do not contain either of these CDR insertions and although the precise architecture by how SpeC may engage these TCRs is unknown, both Tyr 15 and Arg 181 also appear critical for activation of T cells expressing these V␤ domains. It should be noted, however, that significantly lower activation levels of V␤3 ϩ , V␤12 ϩ , and V␤15 ϩ , even in comparison to V␤4.1 ϩ , T cells were reported (31) .
SpeC residues that contact CDR1 include Arg 45 , Tyr 49 , Leu 78 , and Asn 79 , and although only L78A had a dramatic phenotype for the interaction with V␤2.1, the collective binding contribution from each of these likely function to stabilize the overall interaction, accounting for the preferred interaction with V␤2 over V␤4. The results of our integrative approach to mapping the SpeC-V␤2.1 interface support the previously proposed hypothesis that V␤ binding by SpeC is critically dependent on the CDR2 insertion, while the CDR1 insertion is neither critical nor sufficient, but instead augments V␤ binding and T cell activation.
Our results also indicate that of the residues important for engagement of V␤2.1, not all are critical for binding other V␤ domains, such that differences in binding may occur even within an individual V␤ family. Activation of eJRT3-2.1 and the binding data are entirely specific for the V␤2.1 chain used here. Human V␤ families are grouped based on Ͼ75% nucleotide identity, and in humans the V␤2 family has two main isoforms: V␤2.1 and V␤2.2 (9) . Although residues Phe 75 and Leu 78 were critical for binding to soluble V␤2.1 and for activation of eJRT-2.1, the majority of primary V␤2 ϩ T cells were still activated by mutants F75A and L78A, while a subset of V␤2 ϩ T cells were clearly not activated for both of these mutants (Fig. 1B) ϩ T cell activation observed in response to the F75A and L78A SpeC mutants through an alteration in the CDR2 loop, likely centered at the flexible Gly 51 position. This hypothesis, however, remains to be formally tested.
Comparison of the V␤2.1 structure in complex with SpeC (1), with that from a different V␤2.1 chain from an autoimmune TCRp/MHC complex (42) , indicates that the CDR2 loop exists in significantly different conformations when bound to either agonist p/MHC or to SpeC (Fig. 4D) . The side chains of residues Tyr 15 and Arg 181 both sandwich the Ser 52a O ␥ atom through a pair of hydrogen bonds. Assuming movement of CDR2 by engagement with SpeC relative to the autoimmune V␤2.1 TCR, the C ␣ and O ␥ atoms of Ser 52a undergo movements of 4.7 and 5.3 Å, respectively, away from the SpeC surface (Fig. 4D ). This observation is also consistent with plasticity of the CDR2 loop in mouse V␤8.2 upon engagement with SEC3 (43) . Furthermore, previous work using random mutagenesis targeting mouse V␤8.2 CDR2 for affinity maturation binding to SEC3 failed to alter two glycine residues (position 51 and 53) (44) , presumably important for flexibility. The flexibility of the CDR2 loop also plays both energetic and functional roles in negative cooperativity in the mouse V␤8.2-SEC3 interaction (43, 45) . Thus, despite the mechanistic diversity with which SAgs engage their TCR V␤ domain ligands, CDR2 plasticity may play a common and important functional role.
Although SAgs are defined by their ability to activate T cells in a V␤-specific manner (8) , our data indicates that fine specificity may exist for SAg targets even within an individual V␤ family, and although some SAgs such as SEB and SEC3 appear to have evolved to target TCR V␤s through mechanisms that may be more dependent on the conformation of the V␤ CDR loops, other SAgs such as SpeC appear to have evolved to target highly specific features of V␤ CDR loops. When combined with other relevant data, such as the CDR3-dependent binding of Mycoplasma arthritidis mitogen (41) , and the apparent V␣ specificity of SEH (46) , SAgs have likely evolved to engage their TCR ligands through a variety of diverse mechanisms. The integrative approach to mapping SAg-TCR interactions (structurally, energetically, and functionally) provides comprehensive descriptions of these engagement mechanisms and affords a greater understanding of SAg-TCR selectivity and cross-reactivity, thereby providing a foundation for a more rationalized approach to SAg antagonism.
